The association between insulin resistance and hepatic fibrosis in patients with chronic hepatitis C: An observational, multicenter study in Turkey

Basit Öğe Kaydı
dc.contributor.authorDökmeci, Abdulkadir
dc.contributor.authorÜstündağ, Yücel
dc.contributor.authorHülagu, Saadettin
dc.contributor.authorTuncer, İlyas
dc.contributor.authorAkdoğan, Meral
dc.contributor.authorDemirsoy, Hüseyin
dc.contributor.authorKöklü, Seyfettin
dc.date.accessioned2020-03-26T18:58:34Z
dc.date.available2020-03-26T18:58:34Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground/Aims: To evaluate the association between insulin resistance and hepatic fibrosis in patients with chronic hepatitis C. Materials and Methods: A total of 104 chronic hepatitis C patients were included in this non-interventional, open-label, observational, multicenter, cross-sectional study conducted at 20 gastroenterology clinics in Turkey. The primary end point was the correlation between stage of hepatic fibrosis and insulin resistance evaluated via the homeostasis model of assessment-insulin resistance index. Confounders of hepatic fibrosis and insulin resistance were the secondary end points. Results: The mean age of patients was 52.8 years; 65.4% were female. Type 2 diabetes was present in 6.8% and insulin resistance noted in 38.0% of patients. Further, 45.7% of the patients had mild (A0/A1) and the remaining had moderate/severe (A2/A3) hepatic necroinflammatory activity. Patient distribution according to Metavir fibrosis stage was as follows: F0/F1 (57.0%); F2 (6.5%); F3 (23.7%); and F4 (12.9%). A univariate analysis revealed significant positive correlations between Metavir fibrosis stage and insulin resistance (r=0.297; p=0.007). Logistic regression analysis showed that significant predictors of insulin resistance were high alanine transaminase levels (odds ratio, 0.97; 95% confidence interval, 0.944-0.997) and liver fibrosis stage (odds ratio, 0.114; 95% confidence interval, 0.021-0.607). Conclusion: Our findings revealed significant associations between insulin resistance and hepatic fibrosis.en_US
dc.description.sponsorshipRoche PharmaceuticalsRoche Holdingen_US
dc.description.sponsorshipThe authors declared that this study has received financial support from Roche Pharmaceuticals.en_US
dc.identifier.doi10.5152/tjg.2014.7829en_US
dc.identifier.endpage552en_US
dc.identifier.issn1300-4948en_US
dc.identifier.issue5en_US
dc.identifier.pmid25417617en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage546en_US
dc.identifier.urihttps://dx.doi.org/10.5152/tjg.2014.7829
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31180
dc.identifier.volume25en_US
dc.identifier.wosWOS:000345023700013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAVESen_US
dc.relation.ispartofTURKISH JOURNAL OF GASTROENTEROLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectChronic hepatitis Cen_US
dc.subjectinsulin resistanceen_US
dc.subjecthepatic fibrosisen_US
dc.titleThe association between insulin resistance and hepatic fibrosis in patients with chronic hepatitis C: An observational, multicenter study in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu